Farthing M J
Department of Gastroenterology, St Bartholomew's Hospital, London, UK.
Digestion. 1993;54 Suppl 1:47-52. doi: 10.1159/000201077.
Octreotide inhibits intestinal motility and reduces gastrointestinal secretions. These actions have led to its evaluation in two postsurgical conditions: dumping syndrome and short bowel syndrome. Octreotide substantially reduces symptoms of early and late dumping and prevents the associated phenomena including the increase in packed cell volume considered to be indicative of reduced plasma volume. Its therapeutic benefit probably relates both to slowing of gastric emptying and small bowel transit and inhibition of the release of putative mediators (peptide hormones) of the vasomotor symptoms. Octreotide also reduces intestinal efflux in some patients with the short bowel syndrome. This can lead to a reduction in the volume of intravenous fluid requirements but does not allow an intravenous fluid-dependent patient to change back to an oral regimen. The major mechanism of octreotide's therapeutic effect in this situation may be its ability to reduce endogenous gastric acid secretion.
奥曲肽可抑制肠道蠕动并减少胃肠道分泌物。这些作用促使其在两种术后情况中得到评估：倾倒综合征和短肠综合征。奥曲肽可显著减轻早发性和迟发性倾倒的症状，并预防相关现象，包括红细胞压积增加，这被认为表明血浆容量减少。其治疗益处可能与胃排空和小肠转运减慢以及对血管舒缩症状的假定介质（肽类激素）释放的抑制有关。奥曲肽还可减少一些短肠综合征患者的肠液外排。这可导致静脉补液需求量减少，但并不能使依赖静脉补液的患者恢复口服治疗方案。在这种情况下，奥曲肽治疗作用的主要机制可能是其减少内源性胃酸分泌的能力。
